Seagen touts full PhII Tukysa data as it plots colorectal cancer expansion
As rumors of a Merck buyout continue to swirl around Seagen, the big Seattle biotech is charging ahead with new data for its cancer drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
